Jason M. Hafron, MD, presents “2025 AUA SUFU Microhematuria Guideline.”
How to cite: Hafron, Jason M. “2025 AUA SUFU Microhematuria Guideline.” Grand Rounds in Urology. Published July 10, 2025. Accessed Jan 2026. https://grandroundsinurology.com/2025-aua-sufu-microhematuria-guideline/
2025 AUA SUFU Microhematuria Guideline – Summary#
Diane K. Newman, DNP, APRN, FNP-C, Adjunct Professor of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, introduces Jason M. Hafron, MD, Chief Medical Officer, Michigan Institute of Urology, Troy, Michigan. In this 22-minute presentation, Dr. Hafron reviews the 2025 AUA/SUFU amendment to the microhematuria guideline, detailing refinements in risk stratification, diagnostic approach, and integrating urinary biomarkers.
The updated guideline emphasizes reducing unnecessary testing while preserving diagnostic accuracy, moving away from the 2012 approach that mandated cystoscopy and CT urogram for all patients. The 2020 iteration introduced individualized risk assessment, and the 2025 amendment advances this by adding a “low/negligible” risk category.
The guideline also underscores the importance of rechecking urinalysis after treating transient causes like UTIs or gynecologic conditions, especially in women. It urges vigilance in distinguishing benign from persistent hematuria and recommends nephrology referral when renal parenchymal disease is suspected.
The presentation includes a quick Q&A conversation with Dr. Newman. Dr. Hafron emphasizes that while adoption may take time, this risk-adapted model aligns more closely with daily clinical practice and can improve resource allocation and patient experience.
